Zions Bancorporation boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 12,266.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,081 shares of the medical research company’s stock after acquiring an additional 4,048 shares during the quarter. Zions Bancorporation’s holdings in Edwards Lifesciences were worth $447,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of EW. Janus Henderson Group PLC lifted its holdings in shares of Edwards Lifesciences by 1,135.0% in the 3rd quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock valued at $67,739,000 after buying an additional 569,525 shares during the period. Grandeur Peak Global Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 7.7% in the 3rd quarter. Grandeur Peak Global Advisors LLC now owns 14,275 shares of the medical research company’s stock valued at $1,560,000 after buying an additional 1,025 shares during the period. Vident Investment Advisory LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $1,228,000. Chevy Chase Trust Holdings Inc. lifted its holdings in shares of Edwards Lifesciences by 2.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 189,789 shares of the medical research company’s stock valued at $20,745,000 after buying an additional 4,376 shares during the period. Finally, RiverPark Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 85.2% in the 3rd quarter. RiverPark Advisors LLC now owns 287,000 shares of the medical research company’s stock valued at $31,372,000 after buying an additional 132,000 shares during the period. 81.82% of the stock is owned by institutional investors.

Edwards Lifesciences Corporation (NYSE EW) opened at $118.05 on Monday. Edwards Lifesciences Corporation has a one year low of $86.55 and a one year high of $121.45. The firm has a market capitalization of $24,977.50, a P/E ratio of 32.69, a P/E/G ratio of 2.11 and a beta of 0.51. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). The firm had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.68 earnings per share. equities analysts predict that Edwards Lifesciences Corporation will post 3.76 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its board has authorized a stock repurchase program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Several analysts have recently commented on the company. BMO Capital Markets reissued a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a report on Friday. Canaccord Genuity reissued a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a report on Wednesday, November 29th. SunTrust Banks set a $124.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences in a report on Friday, September 1st. Finally, BidaskClub cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Six analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $126.43.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $116.45, for a total transaction of $617,185.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The disclosure for this sale can be found here. Insiders have sold 139,580 shares of company stock valued at $14,849,205 in the last three months. 2.13% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Zions Bancorporation Buys 4,048 Shares of Edwards Lifesciences Corporation (EW)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/zions-bancorporation-buys-4048-shares-of-edwards-lifesciences-corporation-ew/1757400.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).